Obesity and hypertension are closely associated risk factors for cardiovascular disease. An increase in body mass index is commonly associated with an increase in blood pressure and weight reduction is recommended as the principal intervention in the obese hypertensive patient. Sibutramine therapy, as part of a programme of diet and exercise, can help achieve marked weight reduction and improve metabolic and other cardiovascular risk factors. In hypertensive patients, weight loss induced by sibutramine has also been found to reduce blood pressure. Studies have shown that in the obese, well-controlled hypertensive patient, sibutramine is a safe and well-tolerated therapy offering the many clinical benefits associated with weight reduction in this high-risk population. International Journal of Obesity (2001) 25, Suppl 4, S20 -S23.
Links between obesity and hypertension
Obesity is well recognised as one of the prime risk factors for the development of hypertension. An increase in body mass index (BMI, kg=m 2 ) is associated with an increase in the prevalence of hypertension in men and women (see Figure 1) .
Thus, 30 -40% of patients with a BMI > 30 have hypertension as defined by recent WHO and Joint National Committee guidelines. 1, 2 Estimates suggest that around twothirds of all patients with hypertension are either overweight or clinically obese -again demonstrating the close links between these two risk factors.
Obesity hypertension is commonly associated with leftventricular hypertrophy, 3 insulin resistance, impaired glucose tolerance, frank type 2 diabetes and dyslipidaemia. Thus, obese hypertensive patients are often at high risk for cardiovascular complications.
Large-scale epidemiological studies of cardiovascular disease incidence and prevalence, such as the Framingham Study 4 and the New Zealand Heart Study, 5 have provided good evidence of the cumulative risks posed by risk factors, including both obesity and hypertension, on the chance of coronary heart disease (CHD) and other cardiovascular complications occurring in any population over time. Intervention and epidemiological studies have shown that reducing one or more of the contributory risk factors will reduce the risks of cardiovascular morbidity. It is reasonable to assume that this will translate into a corresponding decrease in overall cardiovascular mortality.
Weight reduction, achieved by a variety of means, has been associated consistently with a reduction in blood pressure and an improvement in cardiovascular risk profile. 6, 7 Therefore, weight reduction is now recommended as the principal non-pharmacological measure for the overall clinical management of obese hypertensive patients, and may be the single most important way to improve hypertension in overweight patients. Indeed, in the recent 3 y follow-up of the Trials of Hypertension Prevention, intervention participants who lost at least 4.5 kg at 6 months and maintained this weight reduction for the next 30 months had the greatest reduction in blood pressure and a relative risk for hypertension of 0.35 (CI, 0.20 -0.59). 8 However, the long-term success of weight-loss programmes based on diet and exercise alone is notoriously disappointing. Thus, in the Trials of Hypertension Prevention, despite a continuing programme of group meetings and individual counselling focused on dietary change, physical activity and social support over 3 y, mean weight loss in the intervention group at 3 months was only 70.2 kg. In contrast, induction and maintenance of weight loss with sibu-tramine as part of a weight reduction programme has now been well documented in controlled intervention trials. 9 In these trials, sibutramine-induced weight loss was also associated with remarkable improvements in metabolic parameters.
Blood pressure measurement in obese patients
There are a number of issues to be aware of when assessing hypertension and measuring blood pressure in obese patients. Many of these issues also apply when working with patients of normal weight. 10 As a rule, the patient should be seated comfortably for at least 5 min with the arm bared, supported and positioned at the level of the heart. When sitting without support, readings may be as much as 10 mmHg higher because of the isometric exertion needed to support the body and arm. 11 Particularly in obese individuals, given the increased weight of the arm, the effort required for support may be considerable. No caffeine or smoking should be allowed for 30 min prior to the blood pressure measurement.
The width of the cuff bladder should be equal to about two-thirds of the distance from the axilla to the antecubital space and encircle at least 80% of the arm. False high readings may occur with bladders that are either too narrow or too short. The standard cuff which has a bladder of 12Â23 cm is too short for patients with an arm circumference > 33 cm. O'Brien recommends a 12Â26 cm bladder for the majority of adult arms and a 12Â40 cm bladder for obese arms. 12 If the bladder does not completely encircle the arm, care must be taken to place the cuff over the brachial artery, whereby the lower edge of the cuff should be about 2.5 cm above the antecubital space. In extremely obese patients, a thigh cuff may be used with the wide bladder folded on itself or the bladder may be placed on the forearm with auscultation over the radial artery. On each occasion at least two readings should be taken: if these vary by more that 5 mmHg, additional readings should be taken until these are close. The arm and cuff size should be noted for each occasion. Routine measurement of blood pressure and heart rate is a recommended part of the monitoring of treatment with sibutramine.
Sibutramine efficacy and haemodynamic effects
Sibutramine is a novel compound that establishes a new class of drugs for weight management. When administered daily as part of a weight management programme that includes diet and exercise, sibutramine allows patients to lose weight and to maintain energy balance at a lower body weight. Evidence from studies of up to 2 y duration suggest that these benefits of sibutramine treatment are sustainable and long lasting, and show that this treatment has an excellent safety profile.
Sibutramine is a selective serotonin and noradrenaline reuptake inhibitor, which acts centrally to reduce energy intake and attenuate the decline in metabolic rate post weight loss. However, this pharmacological mode of action involving a stimulation of the sympathetic nervous system means that some dose-related cardiovascular effects of treatment are to be expected. In most patients, a mean increase in heart rate of 3 -7 bpm is expected during sibutramine treatment. Sibutramine can also induce a dose-related increase in mean blood pressure of 2 -3 mmHg but its impact on blood pressure is the outcome of sympathetic stimulation and the hypotensive effect sibutramine-induced weight loss. Thus, in the majority of patients, any initial rise in blood pressure is countered by the progressive weight loss seen with treatment and average blood pressure levels fall to below baseline.
As shown below, when patients on sibutramine therapy achieve weight loss of > 5% initial body weight, this is accompanied by a fall in blood pressure which is proportional to weight loss 13 (see Figure 2) . A large-scale primary care study, conducted over 54 weeks comparing the efficacy of sibutramine plus diet and exercise vs diet and exercise alone, included close assessment of the effects of sibutramine on haemodynamic parameters. 14 This study found that the variability in blood pressure within both the control and the sibutramine-treated groups was greater than any drug-related effects on blood pressure. 
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These results were common to both systolic and diastolic blood pressure and emphasise the need to ensure that in clinical practice repeated and proper measurements of blood pressure are taken at rest and with a sufficiently large cuff to avoid a misleading interpretation of the impact of sibutramine on blood pressure.
Furthermore, analysis of data on patient withdrawals from sibutramine clinical studies overall shows that there were no differences in the incidence of cardiovascular events between control and sibutramine (see Table 1 ).
Despite the fact that sibutramine therapy may be associated with self-limited tachycardia, there is no clinical evidence to suggest that this drug has unexpected or marked cardiovascular side effects.
Apart from hypertension, obesity is also associated with profound haemodynamic changes characterised by an increase in plasma volume and cardiac output, resulting in the development of eccentric myocardial hypertrophy. 15 It is therefore of interest that recent data from clinical studies with sibutramine suggest that weight reduction induced by sibutramine may be associated with significant improvements in left ventricular mass.
It would appear that as weight is lost and haemodynamics improve, there is an accompanying regression in left ventricular hypertrophy that is significant for all sibutraminetreated patients (P < 0.01). 16 The long-term cardiovascular benefits of weight reduction after sibutramine treatment have yet to be determined because duration of clinical studies to date is insufficient to provide hard long-term endpoints. Nevertheless, cardiovascular complications reported from post-marketing surveillance do not suggest an increased cardiovascular risk compared to expected rates of cardiovascular morbidity from epidemiological data. 17 All the available evidence suggests that not only is sibutramine effective in producing weight loss but it does not affect the management of hypertension in the obese patient.
Further reassurance comes from an integrated assessment of the multiple effects of sibutramine on the metabolic and haemodynamic risk factors for cardiovascular disease and their predicted effects using the Framingham equations for the likelihood of having a cardiovascular episode in the next 10 y. When the predicted change in CHD risk over 10 y is calculated, it can be estimated that with increasing weight loss resulting from sibutramine treatment, there will be significant reductions in CHD risk.
This analysis, based on data on file, examined the changes in risk factors and utilised formal comparisons between sibutramine and placebo based on the meta-analysis methodology of Whitehead and Whitehead. 18 An absolute CHD risk reduction was shown in sibutramine-treated patients commensurate with weight loss, ie the greater the weight loss, the greater the absolute CHD risk reduction.
Using sibutramine in everyday clinical practice
Data described elsewhere in the symposium show that sibutramine treatment can induce marked improvements in metabolic risk factors that are important in reducing the overall cardiovascular risks associated with obesity. Obese patients with hypertension can achieve improvements in their blood pressure control through weight loss and, in this respect, sibutramine is an important addition to diet and exercise alone in their management. Sibutramine is not contraindicated in patients with controlled hypertension and, as the evidence suggests, this offers clinical benefits to most obese hypertensive patients.
Sibutramine therapy should be discontinued only if a patient experiences a resting heart rate increase of > 10 bpm, or a rise in systolic or diastolic blood pressure of > 10 mmHg at two consecutive visits. Similarly, treatment should be withdrawn in the event of previously well-controlled hypertension shifting to a pattern of blood pressure > 145=90 mmHg on two consecutive visits, or signs of progressive dyspnoea, chest pain and ankle oedema.
Physicians using sibutramine as part of a weight reduction programme are advised to monitor and check heart rate and blood pressure to identify the minority of patients who may experience marked rises in mean blood pressure. Measurements should be made at rest, and taken three times on three separate occasions to provide a truly reliable assessment of blood pressure. Blood pressure needs to be monitored particularly during the first 3 months of a treatment programme.
If this routine monitoring is part of an ongoing patient assessment, physicians can identify patients less suited to sibutramine therapy, while permitting the majority of patients to benefit from the many clinically important effects of sibutramine.
Summary
In summary, obesity and hypertension have synergistic effects leaving the obese hypertensive patients at high risk for a host of cardiovascular and metabolic complications including left ventricular hypertrophy, insulin resistance, impaired glucose tolerance, type 2 diabetes and dyslipidaemia. Sibutramine-mediated weight loss has been shown to positively impact many of these parameters. Minor increases in heart rate and blood pressure are sometimes seen with sibutramine therapy. However, in the majority of patients, any initial rise in blood pressure is countered by the progressive weight loss seen with treatment. As a result the average blood pressure falls to well below baseline. Those patients who fail to lose weight can be withdrawn from therapy.
It is essential that blood pressure is measured correctly. The patient should be seated comfortably for at least 5 min with the arm bared, supported, and positioned at the level of the heart. No caffeine or smoking should be allowed for 30 min prior to the blood pressure measurement. On each occasion at least two readings should be taken: if these vary by more that 5 mmHg, additional readings should be taken until these are close.
Routine measurement of blood pressure and heart rate is a recommended part of the monitoring of treatment with sibutramine.
